N Engl J Med. 2019 Mar 21;380(12):1128-1138. doi: 10.1056/NEJMoa1813751.
PMID:30893533
Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults.
Hamard J, Rousseau V, Durrieu G, Garcia P, Yrondi A, Sommet A, Revet A, Montastruc F.
BMJ Ment Health. 2024 Apr 12;27(1):e300876. doi: 10.1136/bmjment-2023-300876.
PMID:38609318
Efficacy of probiotic supplements in improving the symptoms of psychosis, anxiety, insomnia, and anorexia due to amphetamine and methamphetamine use: a randomized clinical trial.
Badrfam R, Zandifar A, Hajialigol A, Rashidian M, Schmidt NB, Morabito D, Qorbani M, Shahrestanaki E, Mehrabani Natanzi M.
Psychopharmacology (Berl). 2024 Jul;241(7):1463-1476. doi: 10.1007/s00213-024-06577-x. Epub 2024 Mar 21.
PMID:38512593
Characteristics of Amphetamine Psychosis with Respect to the Length of Drug Exposure.
Babina A, Sokolova I, Vysotskyi M.
CNS Neurol Disord Drug Targets. 2023;22(4):599-606. doi: 10.2174/1871527321666220726141936.
PMID:35894470
Psychosis Risk With Prescription Amphetamine.
Tamminga CA.
Am J Psychiatry. 2024 Oct 1;181(10):856-857. doi: 10.1176/appi.ajp.20240732.
Comparison of serious adverse effects of methylphenidate, atomoxetine and amphetamine in the treatment of ADHD: an adverse event analysis based on the FAERS database.
Wu L, Zhao D, Lan Y, Jin L, Yang L.
BMC Pharmacol Toxicol. 2025 Feb 20;26(1):38. doi: 10.1186/s40360-025-00868-5.
PMID:39980035
Captagone & Morbid Jealousy.
Shalaby AS, Badr Nassar OM, Bahanan AO, Alshehri MH, Nasr Abou Elzahab NF.